SCHEMBL31094168

SCHEMBL31094168

C[C@@H](OC(C)(C)C)[C@H](NC(=O)CNC(=O)[C@H](CCC(=O)NC(c1ccccc1)(c1ccccc1)c1ccccc1)NC(=O)[C@H](COC(C)(C)C)NC(=O)[C@H](Cc1cn(C(c2ccccc2)(c2ccccc2)c2ccccc2)cn1)NC(=O)OC(C)(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ REN P00797 7/20 0.38
▸ ACE P12821 1/20 0.36
▸ NMBR P28336 1/20 0.36
▸ CTSS P25774 2/20 0.36
▸ CTSL P07711 1/20 0.36
▸ CTSB P07858 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ SIRT2 Q8IXJ6 2/20 0.35
▸ PSMB1 P20618 1/20 0.35
▸ PSMB8 P28062 1/20 0.35
▸ PSMB9 P28065 1/20 0.35
▸ PSMB5 P28074 1/20 0.35
▸ PSMB10 P40306 1/20 0.35
▸ PSMB2 P49721 1/20 0.35
▸ AKT1 P31749 1/20 0.35
▸ CCKAR P32238 2/20 0.35
▸ CCKBR P32239 2/20 0.35
▸ OPRD1 P41143 2/20 0.35
▸ PTPN1 P18031 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31094172 0.94 NMBR (0.38) RENNMBRSIRT2
SCHEMBL30096878 0.89 REN (0.37) RENACECTSSCTSLCTSB
SCHEMBL34461946 0.89 REN (0.39) RENPSMB5CCKARCCKBROPRD1
SCHEMBL30524340 0.89 PSEN1 (0.37) RENNMBRCTSSCTSLCTSB
SCHEMBL31614440 0.88 REN (0.41) RENACEPSMB1PSMB8PSMB9
SCHEMBL30343346 0.88 PSEN1 (0.36) RENNMBROPRD1
SCHEMBL31210152 0.87 PSMB8 (0.37) RENPSMB8PSMB9PSMB5CCKAR
SCHEMBL30250211 0.87 OPRD1 (0.36) CCKARCCKBROPRD1
SCHEMBL29475292 0.87 NMBR (0.40) RENNMBRCTSSCTSLCTSB
SCHEMBL34461945 0.87 REN (0.40) RENCCKARCCKBROPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4655312-A1 A PROCESS FOR THE PREPARATION OF GLUCAGON Biocon Limited (IN) 2025-12-03 — — EP claimed
WO-2024157198-A1 A PROCESS FOR THE PREPARATION OF GLUCAGON BIOCON LIMITED (IN) 2024-08-02 — — WO claimed
US-20260042810-A1 A PROCESS FOR THE PREPARATION OF GLUCAGON BIOCON LTD (IN) 2026-02-12 — — US disclosed
EP-4655312-A1 A PROCESS FOR THE PREPARATION OF GLUCAGON Biocon Limited (IN) 2025-12-03 — — EP disclosed
WO-2024157198-A1 A PROCESS FOR THE PREPARATION OF GLUCAGON BIOCON LIMITED (IN) 2024-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042810-A1 A PROCESS FOR THE PREPARATION OF GLUCAGON IAPP, GLP1R, GCG REN 783/4885ACE 3621/4885NMBR 2449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback